Green Clinic and Research Center, Alexandria, Egypt.
Clin Interv Aging. 2013;8:975-81. doi: 10.2147/CIA.S44777. Epub 2013 Jul 24.
Mild cognitive impairment encompasses the clinical continuum between physiologic age-related cognitive changes and dementia. A variety of medications, including herbal preparations (in particular Ginkgo biloba and Panax ginseng), have been advocated as treatments for cognitive impairment in the elderly. In this study, we investigated the effect of an already marketed dietary supplement (Memo®) combining 750 mg of lyophilized royal jelly with standardized extracts of G. biloba 120 mg and P. ginseng 150 mg on Mini-Mental State Examination (MMSE) scores in patients with mild cognitive impairment.
Sixty-six subjects presenting with forgetfulness and satisfying the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) clinical criteria for mild cognitive impairment were randomly divided into an experimental group treated with one Memo capsule before breakfast daily for 4 weeks and a control group who took placebo. The mean change in MMSE score from baseline and reported adverse effects were compared between the two groups.
The mean change in MMSE score in the group treated with Memo for 4 weeks was significantly greater than in the control group (+2.07 versus +0.13, respectively) by the Student's t-test (t = 6.485, P < 0.0001). This was also true after adjusting for age as a covariate and educational level as a factor nested within the treatment groups in a general linear model (analysis of covariance, F = 9.675 [corrected model], P < 0.0001).
This combined triple formula may be beneficial in treating the cognitive decline that occurs during the aging process as well as in the early phases of pathologic cognitive impairment typical of insidious-onset vascular dementia and in the early stages of Alzheimer's disease. Larger-sized studies with longer treatment durations are needed to confirm this.
轻度认知障碍涵盖了生理年龄相关认知变化与痴呆之间的临床连续谱。包括草药制剂(特别是银杏叶和人参)在内的多种药物已被提倡用于治疗老年人的认知障碍。在这项研究中,我们研究了一种已上市的膳食补充剂(Memo®)对轻度认知障碍患者的 Mini-Mental State Examination(MMSE)评分的影响,该补充剂含有 750mg 冻干蜂王浆,以及标准化的银杏叶提取物 120mg 和人参提取物 150mg。
66 名出现健忘症状且符合《精神障碍诊断与统计手册》第四版修订版(DSM-IV-TR)轻度认知障碍临床标准的患者被随机分为实验组和对照组。实验组每天早餐前服用 1 粒 Memo 胶囊,共 4 周,对照组服用安慰剂。通过学生 t 检验比较两组患者 MMSE 评分的基线变化和报告的不良反应。
经过 4 周治疗后,实验组 MMSE 评分的平均变化明显大于对照组(分别为+2.07 分和+0.13 分),差异具有统计学意义(t = 6.485,P < 0.0001)。在校正年龄作为协变量和将教育水平作为嵌套在治疗组内的因素后,这一结果在一般线性模型(协方差分析)中仍然成立(F = 9.675[校正模型],P < 0.0001)。
这种三联配方可能对治疗衰老过程中发生的认知下降以及隐匿性起病的血管性痴呆和阿尔茨海默病早期阶段的病理性认知障碍有一定的益处。需要更大规模、更长治疗时间的研究来证实这一点。